Covid-19

#Astex Pharmaceuticals #Bioorthogonal chemistry #Click chemistry #Cognitive impairment #Covid-19 #Drug discovery #Life sciences #Long Covid #Molecular Biology #Neuroscience #Public health

Podcast: Innovative approaches to improving drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative approaches to improving drug discovery”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Post-Covid cognitive impairment: a new target for drug development?, Sitting Down… Read More

#News

Antibodies attack Covid-19
#Antibody #Covid-19 #Icahn School of Medicine #Immunology / Virology & Vaccines #Nanobodies #Virus mutation

Antibody platform overcomes mutational escape in Covid-19

Scientists have developed a unique antibody platform to tackle the challenges of treating rapidly evolving viruses like SARS-CoV-2 due to their ability to mutate and evade therapies. Their findings introduce the Adaptive Multi-Epitope Targeting and Avidity-Enhanced (AMETA) Nanobody Platform. Dr Yi Shi, Associate Professor… Read More

#Editor's Choice #News

#Biological threats #Covid-19 #European Commission #Fabentech #Funding #Pandemic response

€20 million EIB financing to combat biological threats

The European Investment Bank (EIB) and the French biopharmaceutical company Fabentech have signed a €20 million loan to accelerate the development of broad-spectrum therapeutics to combat biological threats to public health. The deal is supported by the Health Emergency Preparedness and Response Authority (HERA), set up… Read More

#News

T cell attacking Covid-19
#Anti-virals #Covid-19 #Hyundai Bioscience #Long Covid #University of California San Diego

Hyundai Bioscience investigates antiviral for long Covid in US trial

Hyundai Bioscience USA and the University of California San Diego (UCSD) have agreed to conduct a clinical trial to evaluate the efficacy of Xafty, a niclosamide-based antiviral, in treating long Covid. “This is an outstanding opportunity for UCSD  and Hyundai Bioscience to partner together to tackle… Read More

#News

Ozempic (semaglutide)
#Cardiovascular disease #Covid-19 #Diabetes #GLP-1 #Weight loss

Semaglutide reduces risk of all-cause death

Semaglutide has been found to reduce the rates of all-cause death, including as a result of Covid-19, in those who are overweight or have obesity and established cardiovascular disease without diabetes. The findings were published in JACC, the journal of the American College… Read More

#News #Trending News

Arthritis
#Acute inflammatory conditions #Arthritis #Autoimmune disease #Covid-19 #University of Exeter

Breakthrough reveals new drug target for inflammatory diseases

The discovery of a new regulator affecting immune cells could lead to new treatments to reduce inflammation in diseases including arthritis and severe Covid-19. A large research collaboration, led by the University of Exeter’s MRC Centre for Medical Mycology, has focused on how immune cells sense… Read More

#Editor's Choice #News

Patient on ventilator
#Covid-19 #Covid-19 treatment #Drug repurposing #Francis Crick Institute #Pneumonia #University College London

Repurposed drug treats severe Covid-19 pneumonia

A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe Covid-19 pneumonia in a recent clinical trial. The drug, dornase alfa, could be used to treat other respiratory infections, according to the data from researchers at UCL, UCLH and the Francis Crick… Read More

#News #Trending News

Antibodies attacking virus
#Antibodies #Chiba University #Covid-19 #Immune system

Could auto-antibodies be linked to severe Covid-19?

Researchers have revealed that auto-antibodies block interferon signalling, contributing to severe Covid-19 by impairing the patient’s immune response. Scientists have found that some people who suffered from Covid-19 had auto-antibodies targeting their own type 1 interferons, which are important immune signalling proteins. Factors such… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Anti-inflammatory #Artificial intelligence (AI) #Cancer research #Covid-19 #EpicentRx #Immunology / Virology & Vaccines #Oncology #Polypharmacologic #Precision medicine #Protein binders #Therapeutic targets

New podcast on the significance of drug repurposing

This is the latest episode of the free DDW narrated podcast, titled “Why drug repurposing is so significant for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: AI use in repurposing drugs for Covid-19 and RRx-001: Jack… Read More

#News

Close up of vaccine syringe
#Covid-19 #Covid-19 vaccine #Flu vaccine #Immunology / Virology & Vaccines #Influenza #Moderna

Combination vaccine better than separate flu and Covid-19 jabs

In clinical trials, Moderna’s combination vaccine elicited higher immune responses against influenza (flu) virus and SARS-CoV-2 than licensed flu and Covid-19 vaccines in adults 50 years and older. The Phase III trial investigated mRNA-1083, an investigational combination vaccine against influenza and Covid-19. mRNA-1083 comprises… Read More

#News #Trending News

#Coronavirus #Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Pandemic prevention #University of Cambridge

‘Proactive’ vaccine protects against unknown future coronaviruses

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. This approach to vaccine development is called ‘proactive vaccinology’, where scientists build a vaccine before… Read More

#Editor's Choice #News

Covid-19
#Covid-19 #Immunity #Immunology / Virology & Vaccines #University of Oxford

Study proves value of infection studies in developing new vaccines

A study led by the University of Oxford has successfully investigated human immunity against Covid-19 in people who already have antibodies, with the aim of advancing future vaccines and treatments. The results suggest that previous infection, together with vaccination, offers strong protection against the original Covid-19… Read More

#News

#Breast cancer #Clinical trials #Covid-19 #DDW Highlights podcast #FDA #lcohol Use Disorder #Mergers and acquisitions #Psychedelics

New DDW Highlights podcast: 2 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In another busy week for drug discovery and development, we have seen the FDA… Read More

#News

#Alcohol Use Disorder #Breast cancer #Clinical trials #Covid-19 #FDA #Mergers and acquisitions #Psychedelics

This week in drug discovery (25-29 March) 

News round-up for 25-29 March by DDW Digital Content Editor Diana Spencer. In another busy week for drug discovery and development, we have seen the FDA approval of a monoclonal antibody for emergency use in Covid-19, the launch of trials into innovative new treatments for urea cycle disorders… Read More

#News

#Covid-19 #Covid-19 treatment #FDA #Invivyd #Monoclonal antibodies

FDA approves Covid-19 mAb for emergency use

The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to half-life extended monoclonal antibody (mAb) Pemgarda (pemivibart, or VYD222) for the pre-exposure prophylaxis (prevention) of Covid-19. It is approved in adults and adolescents (12 years of age and older weighing at least… Read More

#News